IL165295A0 - Salts of compounds that inhibit thrombin followingadministration to mammalian patients, pharmaceuti cal compositions containing such salts and processes for obtaining them - Google Patents

Salts of compounds that inhibit thrombin followingadministration to mammalian patients, pharmaceuti cal compositions containing such salts and processes for obtaining them

Info

Publication number
IL165295A0
IL165295A0 IL16529503A IL16529503A IL165295A0 IL 165295 A0 IL165295 A0 IL 165295A0 IL 16529503 A IL16529503 A IL 16529503A IL 16529503 A IL16529503 A IL 16529503A IL 165295 A0 IL165295 A0 IL 165295A0
Authority
IL
Israel
Prior art keywords
salts
followingadministration
compounds
obtaining
processes
Prior art date
Application number
IL16529503A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL165295A0 publication Critical patent/IL165295A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL16529503A 2002-05-31 2003-05-27 Salts of compounds that inhibit thrombin followingadministration to mammalian patients, pharmaceuti cal compositions containing such salts and processes for obtaining them IL165295A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201661A SE0201661D0 (sv) 2002-05-31 2002-05-31 New salts
PCT/SE2003/000859 WO2003101957A1 (en) 2002-05-31 2003-05-27 New salts

Publications (1)

Publication Number Publication Date
IL165295A0 true IL165295A0 (en) 2005-12-18

Family

ID=20288039

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16529503A IL165295A0 (en) 2002-05-31 2003-05-27 Salts of compounds that inhibit thrombin followingadministration to mammalian patients, pharmaceuti cal compositions containing such salts and processes for obtaining them

Country Status (31)

Country Link
US (2) US7273858B2 (de)
EP (2) EP2055696A1 (de)
JP (1) JP4541140B2 (de)
KR (1) KR20050009726A (de)
CN (2) CN101735131A (de)
AR (1) AR039937A1 (de)
AT (1) ATE425963T1 (de)
AU (1) AU2003232871B2 (de)
BR (1) BR0311365A (de)
CA (1) CA2487509A1 (de)
CY (1) CY1109085T1 (de)
DE (1) DE60326720D1 (de)
DK (1) DK1513806T3 (de)
ES (1) ES2322048T3 (de)
HK (1) HK1073102A1 (de)
IL (1) IL165295A0 (de)
IS (1) IS7598A (de)
MX (1) MXPA04011912A (de)
MY (1) MY133333A (de)
NO (1) NO329064B1 (de)
NZ (2) NZ554323A (de)
PL (1) PL373794A1 (de)
PT (1) PT1513806E (de)
RU (2) RU2345064C2 (de)
SA (1) SA03240440B1 (de)
SE (1) SE0201661D0 (de)
SI (1) SI1513806T1 (de)
TW (2) TWI313173B (de)
UA (1) UA81246C2 (de)
WO (1) WO2003101957A1 (de)
ZA (1) ZA200409228B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
EP1732932B1 (de) * 2004-04-09 2012-03-21 Hanmi Holdings Co., Ltd. Kristallines clopidogrelnaphthalinsulfonat oder hydrat davon, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die dieses enthält
ZA200608035B (en) * 2004-04-20 2008-07-30 Sanofi Aventis Clopidogrel salt and polymorphic forms thereof
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (de) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV Protease-Hemmer
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
TW201303B (de) * 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
NZ245039A (en) 1991-11-12 1994-12-22 Lilly Co Eli N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
CA2131367A1 (en) 1992-03-04 1993-09-16 Sandor Bajusz New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
TW223629B (de) * 1992-03-06 1994-05-11 Hoffmann La Roche
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9301912D0 (sv) 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
US5783563A (en) 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
EP0648780A1 (de) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterozyklische Thrombinhemmer
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (en) 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
US5705487A (en) 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
US5510369A (en) 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
NZ302649A (en) 1995-02-17 2000-01-28 Basf Ag Dipeptide amidine derivatives, preparation and pharmaceutical compositions thereof
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5695781A (en) 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
AU698911B2 (en) 1995-04-04 1998-11-12 Merck & Co., Inc. Thrombin inhibitors
US5629324A (en) 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9601556D0 (sv) 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
US5863929A (en) * 1996-06-25 1999-01-26 Eli Lilly And Company Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
SE9603724D0 (sv) 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
IL141688A0 (en) 1998-09-04 2002-03-10 Scios Inc Hydrogel compositions for the controlled release administration of growth factors
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
WO2000042059A1 (en) 1999-01-13 2000-07-20 Astrazeneca Ab New amidinobenzylamine derivatives and their use as thrombin inhibitors
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
MXPA03000643A (es) 2000-08-16 2003-06-06 Astrazeneca Ab Nuevos derivados de amidino y su uso como inhibidores de trombina.
SE0102921D0 (sv) 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) * 2003-11-28 2003-11-28 Astrazeneca Ab New process
GB0503672D0 (en) * 2005-02-23 2005-03-30 Astrazeneca Ab New process
GB0510546D0 (en) * 2005-05-24 2005-06-29 Astrazeneca Ab New process
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
AU2003232871B2 (en) 2010-08-19
KR20050009726A (ko) 2005-01-25
RU2004133388A (ru) 2005-07-10
EP1513806B1 (de) 2009-03-18
IS7598A (is) 2004-12-15
AR039937A1 (es) 2005-03-09
AU2003232871A1 (en) 2003-12-19
NO20044867L (no) 2004-12-23
TWI313173B (en) 2009-08-11
SI1513806T1 (sl) 2009-06-30
JP4541140B2 (ja) 2010-09-08
US7763597B2 (en) 2010-07-27
ES2322048T3 (es) 2009-06-16
MXPA04011912A (es) 2005-03-31
RU2345064C2 (ru) 2009-01-27
US20050234035A1 (en) 2005-10-20
EP2055696A1 (de) 2009-05-06
NZ536738A (en) 2007-05-31
TW200927094A (en) 2009-07-01
MY133333A (en) 2007-11-30
CN101735131A (zh) 2010-06-16
BR0311365A (pt) 2005-03-01
CA2487509A1 (en) 2003-12-11
US7273858B2 (en) 2007-09-25
PT1513806E (pt) 2009-05-04
CN1656067A (zh) 2005-08-17
TW200402293A (en) 2004-02-16
SA03240440B1 (ar) 2008-02-24
UA81246C2 (en) 2007-12-25
DK1513806T3 (da) 2009-06-15
DE60326720D1 (de) 2009-04-30
EP1513806A1 (de) 2005-03-16
WO2003101957A1 (en) 2003-12-11
TWI367754B (en) 2012-07-11
ZA200409228B (en) 2005-05-17
US20080269176A1 (en) 2008-10-30
NZ554323A (en) 2008-10-31
HK1073102A1 (en) 2005-09-23
PL373794A1 (en) 2005-09-19
CY1109085T1 (el) 2012-05-23
RU2008127541A (ru) 2010-01-20
SE0201661D0 (sv) 2002-05-31
ATE425963T1 (de) 2009-04-15
JP2005532346A (ja) 2005-10-27
NO329064B1 (no) 2010-08-09

Similar Documents

Publication Publication Date Title
HK1086485A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EP1539730A4 (de) Neue verbindungen, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren anwendung
TW200514772A (en) Novel tetrahydropyridine derivatives
IL151459A0 (en) Novel malonic acid derivatives, processes for their preparation, their use as inhibitors of factor xa activity and pharmaceutical compositions containing them
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
UA93425C2 (ru) Производные гидантоина, которые применяются kak mmp ингибиторы
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
WO2003059898A3 (en) Eponemycin and epoxomicin analogs and uses thereof
MXPA05010137A (es) Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
HK1091376A1 (en) Compositions and methods of formulation for enteral formulas containing sialic acid
TW200626593A (en) Novel compounds
UA90285C2 (ru) Производные гидантоина, полезные как ингибиторы металлопротеиназ
TW200726758A (en) New pyridine analogues
NO20085212L (no) Nye pyridinanaloger
TW200635916A (en) Compounds
IL165295A0 (en) Salts of compounds that inhibit thrombin followingadministration to mammalian patients, pharmaceuti cal compositions containing such salts and processes for obtaining them
TW200621773A (en) Bicyclononene derivatives
IL179530A0 (en) Novel compounds, pharmaceutical compositions containing same and methods of use for same
MY136859A (en) Pyrrolidine derivatives as factor xa inhibitors
TW200628468A (en) Bicyclononene derivatives
MXPA05011497A (es) Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace).
GB0228552D0 (en) Chemical compounds
EP1680104A4 (de) Zusammensetzung zur behandlung von osteoarthritis mit apigenin als chindroregeneratives mittel
TW200621774A (en) Bicyclononene derivatives